Why the study?
Do the benefits of beta-blockers outweigh the risks of life-threatening asthma in post-myocardial infarction patients with asthma?
Do the benefits of beta-blockers outweigh the risks of life-threatening asthma in post-myocardial infarction patients with asthma?
Low-dose beta1-blockers may be considered in post-MI patients with mild or well-controlled asthma, but should be avoided in those with moderate to severe asthma.
Answers are grounded in this paper and cite their sources.
Low-dose beta1-blockers may warrant consideration in select post-MI patients with mild asthma; leaves open need for randomized confirmation.
beta-Blockers are well documented to prolong life in patients after myocardial infarction (MI), yet patients who also have asthma are frequently and understandably denied this therapy. We reviewed the literature (via MEDLINE) for the past 35 years for beta-blocker-induced asthma, and reexamined potential beta-blocker use in the context of NIH guidelines for asthma classification and management. Because beta-blockers can cause fatal or life-threatening asthma, their use should be avoided in moderate to severe persistent asthmatics. Benefits of low-dose beta(1)-blockers (e.g. atenolol 50 mg daily) may outweigh risks in some patients with mild intermittent or well-controlled mild persistent asthma. Further study is needed to verify that low doses of beta(1)-blockers are effective in prolonging life after MI, and that use specifically in mild intermittent or mild persistent asthma per NIH classification is safe.
No takes yet. Share an insight, caveat, or question.
Chafin et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: